TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03372902

Intervention type: DEVICE
Intervention: Breast MRI
Description: Participants with dense breast tissue will get a mammogram and MRI

Intervention type: DEVICE
Intervention: Breast MRI
Description: Participants with dense breast tissue will get a mammogram and MRI

Intervention type: DEVICE
Intervention: Breast Mammogram
Description: State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.

Intervention type: DEVICE
Intervention: Breast Mammogram
Description: State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.

Intervention type: OTHER
Intervention: Blood draw
Description: Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.

Intervention type: OTHER
Intervention: Blood draw
Description: Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.

Intervention type: PROCEDURE
Intervention: Breast Biopsy
Description: Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.

Intervention type: BEHAVIORAL
Intervention: online participant reported questionnaire
Description: Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.

Intervention type: BEHAVIORAL
Intervention: online participant reported questionnaire
Description: Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
Study: NCT03104270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide PO at 3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
Study: NCT00830492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: cycle day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotopin (HMG)
Description: 75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Description: Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
Study: NCT01073930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PicoPrep
Description: PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HalfLytely
Description: HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisacodyl
Description: Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
Study: NCT02327988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Study: NCT01609998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza DNA vaccine
Description: VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza DNA vaccine
Description: VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza DNA vaccine
Description: VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza DNA vaccine
Description: VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
Study: NCT04934644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Description: Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
Study: NCT01209078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: GSK1322322 1500mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid 600mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1322322 placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid placebo
Description: placebo
Study: NCT02699203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meal
Description: Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
Study: NCT02639104

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiography
Description: Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electromyography
Description: Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms.
Study: NCT02331225

Intervention type: OTHER
Intervention: No intervention given
Description: There is no intervention for this study

Intervention type: OTHER
Intervention: No intervention given
Description: There is no intervention for this study

Intervention type: OTHER
Intervention: No intervention given
Description: There is no intervention for this study
Study: NCT03121092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI or ARB
Description: Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
Study: NCT02504697

Intervention type: OTHER
Intervention: Biosamples from airway and blood
Description: Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
Study: NCT03970369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Personalized goals and an activity prescription.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Personalized goals and an activity prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitor
Description: Participants wear a step counter to track activity goals.
Study: NCT03291652

Intervention type: DIAGNOSTIC_TEST
Intervention: DSA/3DRA
Description: DSA/3DRA

Intervention type: DIAGNOSTIC_TEST
Intervention: DSA/3DRA
Description: DSA/3DRA
Study: NCT02374567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study: NCT02356783

Intervention type: DEVICE
Group type: OTHER
Intervention: Pedometer
Description: Wireless pedometer

Intervention type: DEVICE
Group type: OTHER
Intervention: Pedometer
Description: Wireless pedometer
Study: NCT01853046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
Study: NCT01948817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox 20mg/kg taken BID
Study: NCT02355691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREVENA
Description: The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
Study: NCT04479956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicose vein surgery
Description: sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicose vein surgery
Description: sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicose vein surgery
Description: sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicose vein surgery
Description: sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
Study: NCT03210870

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nutritional education classes
Description: The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
Study: NCT04430777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Administration of tranexamic acid 1 gr either intravenously or subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: Administration of tranexamic acid 1 gr either intravenously or subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Administration of tranexamic acid 1 gr either intravenously or subcutaneously
Study: NCT01940809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04005924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arabinogalactan
Description: Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arabinogalactan
Description: Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
Study: NCT00930319

Intervention type: OTHER
Intervention: Firmagon given by prescription according to SPC
Description: Non-interventional,observational Firmagon given by prescription according to SPC
Study: NCT01434732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
Study: NCT03103464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care Therapy + Sit-to-Stand Therapy
Description: Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Therapy
Description: Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
Study: NCT01375491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: generic doxycycline 100mg twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to doxycycline
Study: NCT04415931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Description: Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Standard interscalene brachial plexus regional block
Study: NCT03472339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
Study: NCT01310491

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Health coaching
Description: Telephone based health coaching supported by tele-monitoring.